Circulating FGF23 starts to rise in early stage CKD before the development of other abnormalities such as high parathyroid and phosphate levels and low calcium and 1,25(OH)2D levels.
Investigators found a U-shaped relationship between serum intact parathyroid hormone levels and death risk in Chinese patients initiating hemodialysis.
Tenapanor inhibits the sodium hydrogen exchanger 3 (NHE3), reducing paracellular uptake of phosphate in the intestine.
Nicotinamide modulates expression of the sodium-dependent phosphate cotransporter 2b and thereby may inhibit intestinal phosphate absorption, according to investigators.
Study findings reinforce the value of treating anemia during the transition to dialysis and illustrate the problem of ESA hyporesponsiveness.
Vascular calcification is the most likely mechanism underlying the association between hyperphosphatemia and mortality, according to investigators.
Investigators found a clinically significant difference in systolic blood pressure among patients with stage 3b to 4 chronic kidney disease taking and not taking lanthanum carbonate.
Study data illustrate the potential benefits of controlling serum phosphate, intact parathyroid hormone, and calcium levels in patients with nondialysis-dependent chronic kidney disease.
In a large US study, only half of patients with stage 3, 4, and 5 had undergone PTH retesting at 12, 8, and 4.5 months, respectively, after treatment with vitamin D sterols, in line with KDIGO guidelines.
Study results show that mortality among hemodialysis patients declined from 2006 to 2015 compared with the general Swedish population.
